Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.

British journal of clinical pharmacology - 1 Aug 2011

Malhotra Bimal, Darsey Edress, Crownover Penelope, Fang Juanzhi, Glue Paul

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Tolterodine and 5-hydroxymethyl tolterodine (5-HMT) are equipotent active moieties of tolterodine; 5-HMT is the singular active moiety of fesoterodine. The formation of 5-HMT from tolterodine occurs via CYP2D6, and some subjects are poor metabolizers CYP2D6. On the other hand, the formation of 5-HMT from fesoterodine occurs via ubiquitous esterases. Cross-study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzhydryl Compounds

Share to Biological Availability

Share to Cresols

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Muscarinic Antagonists

Source

Open in PubMed Open full text

Identifiers

PMID: 21352267
DOI: 10.1111/j.1365-2125.2011.03948.x
PMCID: PMC3162652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.PMID 21352267Read ↗

Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.Semantic proximity Read ↗

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.Semantic proximity Read ↗

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.Semantic proximity Read ↗

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.Semantic proximity Read ↗

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.Semantic proximity Read ↗

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.Semantic proximity Read ↗

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.Semantic proximity Read ↗

Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.